The National Drug Administration approves Roche Pharmaceuticals Partett ® joint quto-bead and chemotherapy for new complementary treatment sparing for early breast cancer patients

Recently, RochePharmaceutical(http:// announcedthat its breast cancer innovation target drug Partet ® (Perjeta ®, generic name: Patojusmono) has been approved by China's NationalDrug(http://Supervision Authority, combined quto-bead mono-resistance and chemotherapy for HER2-positive local late stage, inflammatory or early breast cancer patients (diameter 2cm or lymph node sympathis)The ® and Herceptin ® a two-target treatment that enables 40%-60% of HER2-positive early breast cancer patients to achieve preoperative complete demission (pCR), i.ecancer cells disappear in breast tissue and armpit lymph nodesAt present, in the new auxiliary treatment, quto-zhu-contment anti-combined patozumab as part of her2-positive early breast cancer system treatment program has been China and the international recommendations of a number of breast cancer treatment guidelines and expert consensusThe new assistive indications approved by the State Drug Administration of China® are based mainly on theof the http:// of the PEONY ClinicalTrial
trialThe study was the first phase III trial based on new complementary two-target, randomized, multi-center, double-blind, and placebo-controlled experiments based on asian populationsIn October 2013, The new assistive indications ® received accelerated approval from theAdministration of food anddrugs(http://(
FDA(http://, based primarily on the results of neoSphere researchAt the time, the Padter ® treatment program was the first FDA-approved drug to acquire new complementary treatment stors for breast cancer based on the fast-track approval principleAccording to neoSphere Phase II clinical trial results show that the proportion of pathological total remission (tpCR) was 39.3% through the new auxiliary treatment of dositarace and quto-bead monoantigens over a period of 4 cycles, which was nearly double that compared to the simple qutobermono-resistance regimen